Navigation Links
Stomach stem cell discovery could bring cancer insights
Date:10/3/2007

portant goal for decades.

Before this work, we knew that stem cells existed in the stomach, but we had no way to precisely identify them, says Gumucio, who directs the U-M Center for Organogenesis and is a professor in the Department of Cell and Developmental Biology at the U-M Medical School.

There were no effective markers or tags that we could use to clearly discriminate the stem or progenitor cells from other cells. Now, for the first time, we have the experimental tools to ask important questions, like, Does stomach cancer really arise from mutations in this progenitor cell population"

Stomach cancer is a major cancer killer outside the United States. It is the most common

cause of cancer deaths in much of East Asia and Latin America. In the United States, it is estimated that 21,260 people will be diagnosed with stomach cancer and 11,210 will die of it in 2007.

There are several types of stomach cancer, but one very prevalent type, called intestinal-type gastric adenocarcinoma, progresses through a defined series of steps. Initially, the insult is an inflammatory one, usually through infection by an acid-tolerant bacterium called Helicobacter pylori. The chronic inflammation eventually leads to changes in the character of the surrounding stomach cells and ultimately, over several years, to tumors. These tumors often arise in one particular area of the stomach. Interestingly, the progenitor cells that the Gumucio lab has identified are concentrated precisely in this tumor-prone area.

To spot and watch the progenitor cells at work, Gumucios team, under lead author Xiaotan T Qiao, Ph.D., a U-M Medical School research associate, had to get past the hurdle that has deterred the search for stomach stem cells so far finding effective markers, which act like identification tags to make tracing possible. Qiao was able to identify the gastric progenitor cells and later explore their behavior because the cells
'/>"/>

Contact: Anne Reuter
arueter@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Unraveling a stomach cancer puzzle
2. Stomach receptor for H. pylori discovered
3. Salmonella survives better in stomach due to altered DNA
4. Prehistoric origins of stomach ulcers uncovered
5. Protein discovery could unlock the secret to better TB treatment
6. Purdue proves concept of using nano-materials for drug discovery
7. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
8. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
9. UCSD Discovery Shows How Embryonic Stem Cells Perform Quality Control Inspections
10. Discovery Could Lead To Novel Approaches In HIV Treatment
11. UCSD discovery may help extend life of natural pesticide
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2